NCT06695026 is a Phase 1/Phase 2 clinical trial of RZ-001 Dose 1 in Hepatocellular Carcinoma (HCC), sponsored by Rznomics, Inc..

Who is sponsoring NCT06695026?

NCT06695026 is sponsored by Rznomics, Inc..

What drugs are being tested in NCT06695026?

Interventions in NCT06695026: RZ-001 Dose 1, RZ-001 Dose 2, RZ-001 Dose 3.

What condition does NCT06695026 study?

NCT06695026 studies Hepatocellular Carcinoma (HCC).

Is NCT06695026 still recruiting?

NCT06695026 is currently recruiting now. Last updated 24 July 2025.

Last reviewed 2025-07-24 · How we verify

NCT06695026

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1b/2a, Open-label, Multicenter, Randomized, Dose Escalation Study Evaluating the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

Recruiting now Phase 1/Phase 2 Last updated 24 July 2025

What this trial tests

Phase 1/Phase 2 trial testing RZ-001 Dose 1 in Hepatocellular Carcinoma (HCC) in 45 participants. Currently enrolling.

Timeline

18 December 2024

Primary endpoint
1 August 2027

1 October 2027

Quick facts

Lead sponsor	Rznomics, Inc.
Phase	Phase 1/Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	18 December 2024
Primary completion	1 August 2027
Estimated completion	1 October 2027
Sites	9 locations across South Korea

Drugs / interventions tested

RZ-001 Dose 1
RZ-001 Dose 2
RZ-001 Dose 3

Conditions studied

Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →

Sponsor

Rznomics, Inc. — full company profile →

Who can join

18 and older, any sex, with Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of participants with adverse events (AEs) as graded by NCI CTCAE
Time frame: Screening visit, up to 2 years
Assessment of tumor response of target lesion where RZ-001 is administered based on the RECIST v1.1 and HCC mRECIST
Time frame: Screening visit, every 2 cycles (each cycle is 3 weeks, 6 weeks) until week 54 & every 3 cycles (each cycle is 3 weeks, 9 weeks) after week 54, up to 2 years
Overall response rate based on RECIST v1.1 and HCC mRECIST
Time frame: Screening visit, every 2 cycles (each cycle is 3 weeks, 6 weeks) until week 54 & every 3 cycles (each cycle is 3 weeks, 9 weeks) after week 54, up to 2 years

Sponsor's own description

This study is to evaluate the safety, tolerability, efficacy and immunogenicity of RZ-001 in combination with Valganciclovir (VGCV) and Atezolizumab/Bevacizumab when given to subjects with human telomerase reverse transcriptase (hTERT)-positive HCC.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Application of Immune Checkpoint Inhibitors in Cancer.
Chen Z, Song Z, Den S, Zhang W, et al · · 2025 · cited 2× · PMID 40787068 · DOI 10.1002/mco2.70176

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma (HCC)

Currently open trials in the same condition.

NCT07070076 — A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Ther · NA · recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07490262 — A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular · Phase 2, PHASE3 · recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other Rznomics, Inc. trials

Trials by the same sponsor.

NCT06676891 — Expanded Access Program for GBM Subjects · available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06695026 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rznomics, Inc.
Last refreshed: 24 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06695026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing